News

Novo Nordisk applies for FDA approval in tightening race for weight loss pill
Novo Nordisk, the Danish maker of Ozempic and Wegovy, announced Tuesday that it has asked the Food and Drug Administration to ...
Think It's Too Late to Buy Novo Nordisk? Here's the Biggest Reason Why There's Still Time.
Almost unarguably, the most significant story in our time with the pharmaceutical industry is the emergence and sharp rise of GLP-1 obesity drugs. Front and center of this is Novo Nordisk (NYSE: NVO), ...
Finanz und Wirtschaft53m
Major investment: Roche’s $50 billion trick
Following competitor Novartis, pharma giant Roche also announces massive investments in the United States. Swiss jobs and ...
Barchart on MSN57m
Eli Lilly's Quarterly Earnings Preview: What You Need to Know
With a market cap of $775.6 billion, Eli Lilly and Company (LLY) is a global biopharmaceutical leader with leading products ...